Share on LinkedInShare on LinkedIn

ARTICLE · 21 JANUARY 2014

Health Canada And Federal Court Make Important Biologic Decisions

Last week was a landmark for biologics in Canada: Health Canada approved two antibody subsequent entry biologics (SEBs) and the Federal Court issued a decision finding a patent directed at a therapeutic use of an antibody to be valid and infringed.

CanadaIntellectual Property

Last week was a landmark for biologics in Canada: Health Canada approved two antibody subsequent entry biologics (SEBs) and the Federal Court issued a decision finding a patent directed at a therapeutic use of an antibody to be valid and infringed.

Health Canada approves first antibody SEBs

On January 15, 2014, Health Canada issued notices of compliance (NOCs) to Celltrion Healthcare Co. Ltd. for REMSIMA and INFLECTRA, which both contain a monoclonal antibody, infliximab, as the medicinal ingredient. Janssen Inc. markets REMICADE, containing infliximab, for a number of indications, including rheumatoid arthritis, Crohn's disease, ulcerative colitis and psoriasis. It is not clear at this time for which indications REMSIMA and INFLECTRA were approved.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from